|
|
|
|
UPDATE 1-Merck CEO faults company's record in 2008 30 mins ago
By Ransdell Pierson NEW YORK, Jan 7 (Reuters) - The chief executive of Merck & Co Inc said on Wednesday several setbacks last year were partly due to poor company execution, including failure to win U.S.approval for its Cordaptive...
|
|
|
UPDATE 1-Merck CEO faults company's record in 2008
By Ransdell Pierson NEW YORK, Jan 7 (Reuters) - The chief executive of Merck & Co Inc said on Wednesday several setbacks last year were partly due to poor company execution, including failure to win U.S.approval for its Cordaptive...
|
|
|
UPDATE 1-Merck CEO faults company's record in 2008
NEW YORK, Jan 7 (Reuters) - The chief executive of Merck & Co Inc said on Wednesday several setbacks last year were partly due to poor company execution, including failure to win U.S.approval for its Cordaptive cholesterol pill or...
|
|
|
UPDATE 1-Merck CEO faults company's record in 2008
By Ransdell Pierson NEW YORK, Jan 7 (Reuters) - The chief executive of Merck&Co Inc (News/Aktienkurs) said on Wednesday several setbacks last year were partly due to poor company execution, including failure to win U.S.approval for...
|
|
|
UPDATE 1-Merck CEO faults company's record in 2008
By Ransdell Pierson NEW YORK, Jan 7 (Reuters) - The chief executive of Merck & Co Inc said on Wednesday several setbacks last year were partly due to poor company execution, including failure to win U.S.approval for its Cordaptive...
|
|
|
UPDATE 1-Merck CEO faults company's record in 2008
(Reuters via COMTEX) -- MRK | Quote | Chart | News | PowerRating -- The chief executive of Merck & Co Inc said on Wednesday several setbacks last year were partly due to poor company execution, including failure to win U.S.
|
|
|
UPDATE 1-Merck CEO faults company's record in 2008
By Ransdell Pierson NEW YORK, Jan 7 (Reuters) - The chief executive of Merck & Co Inc said on Wednesday several setbacks last year were partly due to poor company execution, including failure to win U.S.approval for its Cordaptive...
|
|
|
UPDATE 1-Merck CEO faults company's record in 2008
By Ransdell Pierson NEW YORK, Jan 7 (Reuters) - The chief executive of Merck & Co Inc (MRK.N Richard Clark, speaking at a Goldman Sachs (GS.N The biggest setback was the April rejection of Cordaptive by the U.S.Food and Drug...
|
|
|
Merck CEO: Acquisitions Are Key Priority For 2009
12:04 PM ET Merck & Co.'s (MRK) leader said the drug maker has the resources to make significant acquisitions, but if the company doesn't make big purchases it will return cash to shareholders through dividends or share buybacks.'I...
|
|
|
Pharmaceuticals' spending spree could swallow biotechs
Some of the world's biggest pharmaceuticals companies are likely to embark on a buying spree as imminent patent expiries combine with a greater willingness from biotechs to sell out.The leading pharmaceuticals companies are seeking to...
|
|
|
LegalView Reports Development of a Breakthrough Study Explaining How Asbestos Causes Mesothelioma Cancer
--(PR.com)-- LegalView.com, the most comprehensive legal resource available on the Internet, recently informed its mesothelioma information blog readers of the development of a breakthrough study by Ohio State University researchers as to...
|
|
|
LegalView Reports Development of a Breakthrough Study Explaining How Asbestos Causes Mesothelioma Cancer
LegalView recently reported of a study by scientists at Ohio State University who are attempting to determine the molecular details of how asbestos fibers bind to human cancer cells.The scientists hope that with the study, they will...
|
|
|
LegalView Reports FDA Delay of Drug That Might Prevent OxyContin Drug Abuse
LegalView, the best resource for everything and anything legal on the Web, recently reported on the potential release of a new drug Remoxy, which would likely prevent abuse of similar drugs such as OxyContin.The U.S. Food and Drug...
|
|
|
LegalView Reports FDA Delay of Drug That Might Prevent OxyContin Drug Abuse
DENVER, COLORADO (PRLEAP.COM) Denver, CO LegalView recently reported on the potential release of a new drug Remoxy, which would likely prevent abuse of similar drugs such as OxyContin.The U.S. Food and Drug Administration (FDA)...
|
|
|
FDA partners with WebMD to protect public health, Congresswoman Gillibrand announces
The federal goverment has teamed up with popular health website WebMD.com to inform the public about health alerts and product recalls, as well as offer a way for consumers to report concerns about drugs and consumer products directly to the...
|
|
|
Merck Forms BioVentures Division and Expects to Lead in Follow-On Biologics
By Dow Jones Merck & Co.(MRK) has formed a new division that's developing versions of leading biotechnology drugs, a category seen as a big growth area in coming years. Merck unveiled the new division at a meeting with analysts and...
|
|
|
Drug maker Merck expanding into biotech, emerging markets
WHITEHOUSE STATION, N.J.- Merck & Co. said Tuesday it is taking steps to become a leader in generic biotechnology drugs and sales in emerging markets, diversifying its research through partnerships and new technologies, and...
|
|
|
Drug maker Merck expanding into biotech, emerging markets
file photo, the company logo is seen on the doors of a building at Merck & Co.headquarters in Whitehouse Station, N.J. THE ASSOCIATED PRESS/Mel Evans Find Mutual Funds Enter a search term: Select a Fund Category: Google Currency...
|
|
|
Merck bets on generic biotech in strategic shift
WHITEHOUSE STATION, New Jersey (Reuters) - Merck & Co plans to break into biotechnology medicine, including a major push into the developing market for generic biotech, as it confronts challenges to its product line.The move into...
|
|
|
Merck diversifying into biotechnology generics
READINGTON Drugmaker Merck & Co.said Tuesday it is taking steps to become a leader in generic biotechnology drugs and sales in emerging markets, diversifying its research through partnerships and new technologies, and working to...
|
|
|
Drug maker Merck expanding into biotech, emerging markets
WHITEHOUSE STATION, N.J.- Merck & Co. said Tuesday it is taking steps to become a leader in generic biotechnology drugs and sales in emerging markets, diversifying its research through partnerships and new technologies, and...
|
|
|
Drug maker Merck expanding into biotech, emerging markets
WHITEHOUSE STATION, N.J.- Merck & Co. said Tuesday it is taking steps to become a leader in generic biotechnology drugs and sales in emerging markets, diversifying its research through partnerships and new technologies, and...
|
|
|
Drug maker Merck expanding into biotech
WHITEHOUSE STATION, N.J.-- Merck & Co. said Tuesday it is taking steps to become a leader in generic biotechnology drugs and sales in emerging markets, diversifying its research through partnerships and new technologies, and...
|
|
|
Drug maker Merck expanding into biotech, emerging markets
Linda A.Johnson, THE ASSOCIATED PRESS The Canadian Press, 2008 WHITEHOUSE STATION, N.J. - Merck & Co. said Tuesday it is taking steps to become a leader in generic biotechnology drugs and sales in emerging markets,...
|
|
|
BIOTECH: Merck expanding into biotech, emerging markets
WHITEHOUSE STATION, N.J.---- Drugmaker Merck & Co. said Tuesday it is taking steps to become a leader in generic biotechnology drugs and sales in emerging markets, diversifying its research through partnerships and new...
|
